1-9 of 9
Ranjit Nair, MBBS, MD
Close
Sort by
Journal Articles

Comparative Review of 30 Day Non-Relapse Mortality (NRM) in B-Cell Lymphomas Associated with Anti-CD19 Chimeric Antigen Receptor T-Cells (CAR-T) from FDA Database, Clinical Studies, and MD Anderson

Ethan Burns, MD, Kartik Anand, MD, Jason R. Westin, MD, Sai Ravi Kiran Pingali, MD, Joe Ensor, PhD, Dahlia Sano, MD, Loretta J. Nastoupil, MD MSc, Hun Ju Lee, Yago Nieto, MD PhD, Issa F. Khouri, MD, Felipe Samaniego, MD, Simrit Parmar, MBBS, Michael Wang, MD, Misha Hawkins, Sherry Adkins, ANP, Luis E. Fayad, MD, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, Sattva S Neelapu, MD, Swaminathan P. Iyer, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1931.
https://doi.org/10.1182/blood-2019-131077
Published: 2019
Journal Articles

Results of a Phase II Study of Obinutuzumab in Combination with Lenalidomide in Previously Untreated, High Tumor Burden Follicular Lymphoma (FL)

Loretta J. Nastoupil, MD MSc, Jason R. Westin, MD, Fredrick B. Hagemeister, MD, Hun Ju Lee, Luis Fayad, MD, Felipe Samaniego, MD, Sairah Ahmed, MD, Linda Claret, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Maria Alma Rodriguez, MD, Michael L. Wang, MD, Michael R Green, PhD, Eric Davis, MD, Sattva S Neelapu, MD, Nathan H Fowler, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 125.
https://doi.org/10.1182/blood-2019-129422
Published: 2019
Journal Articles

A Phase I/II Study of Lenalidomide Plus Obinutuzumab in Relapsed Indolent Lymphoma

Nathan H Fowler, MD, Loretta J. Nastoupil, MD MSc, Collin Chin, MBBS, Paolo Strati, MD, Fredrick B. Hagemeister, MD, Luis E. Fayad, MD, Jason R. Westin, MD, Sheryl G Forbes, Janine Arafat, Lei Feng, MS, Ranjit Nair, MBBS,MD, Raphael E Steiner, MD, Felipe Samaniego, MD, Sattva S Neelapu, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 348.
https://doi.org/10.1182/blood-2019-131045
Published: 2019
Journal Articles

A Phase II Trial of Nivolumab and Ibrutinib for Patients with Relapsed or Refractory Central Nervous System Lymphoma

Jason R. Westin, MD, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Sattva S Neelapu, MD, Hun Ju Lee, Fredrick B. Hagemeister, MD, Maria Alma Rodriguez, MD, Raphael E Steiner, MD, Sairah Ahmed, MD, Simrit Parmar, MBBS, Ranjit Nair, MBBS,MD, Rebecca Harrison, MD, Luis Fayad, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 4086.
https://doi.org/10.1182/blood-2019-131463
Published: 2019
Journal Articles

Smart Start: Rituximab, Lenalidomide, and Ibrutinib Alone and in Combination with Standard Chemotherapy for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Final Phase II Results

Jason R. Westin, MD, Loretta J. Nastoupil, MD MSc, Luis Fayad, MD, Fredrick B. Hagemeister, MD, Yasuhiro Oki, MD, Francesco Turturro, MD, Sairah Ahmed, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael Eric Steiner, MD, Ranjit Nair, MBBS,MD, Simrit Parmar, MBBS, Ken H. Young, Timothy J. McDonnell, MD PhD, Hubert Chuang, Michael R Green, PhD, Sattva S Neelapu, MD, Eric Davis, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1581.
https://doi.org/10.1182/blood-2019-128475
Published: 2019
Journal Articles

A Phase I/II Study to Examine the Safety and Efficacy of Pembrolizumab 200 Mg Fixed Dose Administered Every 3 Weeks (Q3W) in Combination with Romidepsin in Relapsed or Refractory Peripheral T-Cell Lymphoma (PTCL)

Swami P. Iyer, MD, Sattva S Neelapu, MD, Ethan Burns, MD, Ranjit Nair, MBBS,MD, Chitra Hosing, MD, Yago Nieto, MD PhD, Jason R. Westin, MD, Simrit Parmar, MBBS, Nathan H. Fowler, MD, Loretta J. Nastoupil, MD MSc, Madeleine Duvic, MD, Roberto N. Miranda, MD, Hun Ju Lee, Felipe Samaniego, MD, Sairah Ahmed, MD, Feng Lei, MS, Auris Huen, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1546.
https://doi.org/10.1182/blood-2019-132278
Published: 2019
Journal Articles

Radiation Therapy Can be an Effective Bridging Strategy Prior to Axicabtagene Ciloleucel Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Chelsea C Pinnix, MD PhD, Jillian R Gunther, MD PhD, Bouthaina S. Dabaja, MD, Sherry Adkins, ANP, Misha Hawkins, Jason R. Westin, MD, Luis Fayad, MD, Sairah Ahmed, MD, Nathan H. Fowler, MD, Fredrick B. Hagemeister, MD, Swaminathan P. Iyer, MD, Maria Alma Rodriguez, MD, Hun Ju Lee, Raphael E Steiner, MD, Ranjit Nair, MBBS,MD, Paolo Strati, MD, Simrit Parmar, MBBS, Felipe Samaniego, MD, Michael Wang, MD, Sattva S Neelapu, MD, Loretta J. Nastoupil, MD MSc
Journal: Blood
Blood (2019) 134 (Supplement_1): 1609.
https://doi.org/10.1182/blood-2019-131499
Published: 2019
Journal Articles

Effect of Timing of Monoclonal Antibody Therapy on the Time to Next Treatment and Response Rate in Heavily Pre-Treated Patients with Myeloma Who Separately Received Both Daratumumab and Elotuzumab-Based Regimens

Melody R. Becnel, MD, M Laura Rubin, PhD, Ranjit Nair, MBBS, MD, Elisabet E. Manasanch, MD, Hans C. Lee, MD, Krina K. Patel, MD MSc, Swaminathan P Iyer, MD, Sheeba K. Thomas, MD, Donna M. Weber, MD, Robert Z. Orlowski, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 3258.
https://doi.org/10.1182/blood-2018-99-115663
Published: 2018
Journal Articles

Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma

Dahlia Sano, MBBCH, Loretta J. Nastoupil, MD, Nathan H. Fowler, MD, Luis Fayad, MD, F. B. Hagemeister, MD, Hun Ju Lee, MD, Felipe Samaniego, MD, Michael Wang, MD, Maria Alma Rodriguez, MD, Swaminathan P Iyer, MD, Simrit Parmar, MBBS, Raphael Steiner, MD, Ranjit Nair, MBBS,MD, Sherry Adkins, ANP, Sara Arafat, MD, Ahalya Rao, MD, Liliana Vallejo, Misha Hawkins, Yiming Chen, Jason R. Westin, MD, Sattva S. Neelapu, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 96.
https://doi.org/10.1182/blood-2018-99-120013
Published: 2018